Tuhura Bio and Kintara Therapeutics announced that the phase 1B clinical trial of Ifx-2.0 had positive results. Ifx-2.0 is a new personalized cancer bio-vaccine used to treat patients with refractory advanced Merkel cell carcinoma (MCC) and cutaneous squamous cell carcinoma (CSCC) who have previously received PD-1, PD-L1 and other checkpoint inhibitors with poor efficacy.
Tuhura生物和kintara therapeutics宣布Ifx-2.0的1B期临床试验的结果是积极的。 Ifx-2.0是一种新型个性化癌症生物-疫苗用于治疗难治性晚期Merkel细胞癌（Mcc）和表皮鳞状细胞癌（Cscc）患者之前使用过PD-1、PD-L1等检查点抑制剂治疗但疗效不佳。
Tuhura Bio and Kintara Therapeutics announced that the phase 1B clinical trial of Ifx-2.0 had positive results. Ifx-2.0 is a new personalized cancer bio-vaccine used to treat patients with refractory advanced Merkel cell carcinoma (MCC) and cutaneous squa
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.